PHARMACOECONOMIC CLAIMS LIMITED TO "ECONOMIC CONSEQUENCES" IN FDA REFORM AMENDMENT; PHASE IV, PET DRUGS AMONG TOPICS MODIFIED FROM MARK-UP OF S 830
The scope of pharmacoeconomic claims allowed under the Senate FDA reform bill would be limited to "the economic consequences, including the costs of the represented health outcomes" of a drug, under the floor version of the S 830 being debated the week of Sept. 8.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth